September 23, 2025 • 4 mins
Welcome to Ozempic Weightloss Unlocked, the podcast where the science and the stories around Ozempic are put into focus for anyone curious about medical breakthroughs, health, and real-world results.
Today we dive into the latest findings shaking up the world of weight management with Ozempic, a brand name for semaglutide. New research published mid-September in The Lancet Diabetes & Endocrinology shows that a triple-sized weekly dose of Ozempic—specifically 7.2 milligrams—helped people with obesity lose even more weight than the currently approved lower dose. Adults who took this higher dose lost on average nearly 19 percent of their body weight. Nearly half of participants on this regimen lost at least 20 percent, and a third lost a quarter or more. Similar benefits were seen for those with type 2 diabetes, with the higher dose leading to a 13 percent weight loss, compared to 10 percent for the lower dose.
But there is more than just the numbers on the scale. Participants on the higher dose saw improvements in waist circumference, blood pressure, blood sugar, and cholesterol numbers. Importantly, the higher dose was found to be both safe and generally well tolerated. The most frequent issues were digestive, like nausea and diarrhea, but these tended to resolve over time with no increased risk of severe low blood sugar or other serious events. Researchers from the Wharton Medical Clinic in Canada concluded that even greater health improvements could be reached in the future, but they called for more research into the long-term effects and safety as use expands.
Adding to the buzz, a recent study out of Denmark raises important questions about how long people actually stick with Ozempic for weight management. According to research presented at the Annual Meeting of The European Association for the Study of Diabetes, more than half of adults who began using the drug for weight loss ended up quitting within one year. Factors behind this drop-off included cost, side effects, and potential health complications. When treatment is stopped, most people regain weight, highlighting that Ozempic is not a short-term fix and needs to be taken long term for sustainable results. The findings raise red flags since discontinuing the medication can undermine hard-won health improvements, and the high price also risks making access unequal.
Ozempic is not just for the scale—it has heart-protective effects too. Novo Nordisk, the pharmaceutical company behind the drug, released results from the REACH trial showing that once-weekly Ozempic reduced the risk of heart attack, stroke, or hospitalization for heart failure by a significant 25 percent compared to an older medication called dulaglutide. That is a substantial bonus, especially for those with both obesity and cardiovascular risk factors.
Researchers are also learning that how you eat can affect how well Ozempic works. A team from Kyoto University found that people who eat in response to sights and smells of food are more likely to see weight loss benefits from Ozempic, compared to those who eat mainly for emotional reasons. Those with emotional eating patterns might require additional behavioral or psychological support for the medication to be most effective.
The science is clear—GLP-1 receptor agonists like Ozempic can be life-changing, delivering substantial and safe weight loss, along with significant improvements for blood sugar, heart health, and metabolic risk factors. But to sustain progress, long-term commitment is key, and the therapy works best alongside changes in eating habits and ongoing support.
Thank you for tuning in to Ozempic Weightloss Unlocked. If you found today’s update helpful, be sure to subscribe for more news and expert insights on this quickly evolving topic. This has been a quiet please production, for more check out quiet please dot ai.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
Today we dive into the latest findings shaking up the world of weight management with Ozempic, a brand name for semaglutide. New research published mid-September in The Lancet Diabetes & Endocrinology shows that a triple-sized weekly dose of Ozempic—specifically 7.2 milligrams—helped people with obesity lose even more weight than the currently approved lower dose. Adults who took this higher dose lost on average nearly 19 percent of their body weight. Nearly half of participants on this regimen lost at least 20 percent, and a third lost a quarter or more. Similar benefits were seen for those with type 2 diabetes, with the higher dose leading to a 13 percent weight loss, compared to 10 percent for the lower dose.
But there is more than just the numbers on the scale. Participants on the higher dose saw improvements in waist circumference, blood pressure, blood sugar, and cholesterol numbers. Importantly, the higher dose was found to be both safe and generally well tolerated. The most frequent issues were digestive, like nausea and diarrhea, but these tended to resolve over time with no increased risk of severe low blood sugar or other serious events. Researchers from the Wharton Medical Clinic in Canada concluded that even greater health improvements could be reached in the future, but they called for more research into the long-term effects and safety as use expands.
Adding to the buzz, a recent study out of Denmark raises important questions about how long people actually stick with Ozempic for weight management. According to research presented at the Annual Meeting of The European Association for the Study of Diabetes, more than half of adults who began using the drug for weight loss ended up quitting within one year. Factors behind this drop-off included cost, side effects, and potential health complications. When treatment is stopped, most people regain weight, highlighting that Ozempic is not a short-term fix and needs to be taken long term for sustainable results. The findings raise red flags since discontinuing the medication can undermine hard-won health improvements, and the high price also risks making access unequal.
Ozempic is not just for the scale—it has heart-protective effects too. Novo Nordisk, the pharmaceutical company behind the drug, released results from the REACH trial showing that once-weekly Ozempic reduced the risk of heart attack, stroke, or hospitalization for heart failure by a significant 25 percent compared to an older medication called dulaglutide. That is a substantial bonus, especially for those with both obesity and cardiovascular risk factors.
Researchers are also learning that how you eat can affect how well Ozempic works. A team from Kyoto University found that people who eat in response to sights and smells of food are more likely to see weight loss benefits from Ozempic, compared to those who eat mainly for emotional reasons. Those with emotional eating patterns might require additional behavioral or psychological support for the medication to be most effective.
The science is clear—GLP-1 receptor agonists like Ozempic can be life-changing, delivering substantial and safe weight loss, along with significant improvements for blood sugar, heart health, and metabolic risk factors. But to sustain progress, long-term commitment is key, and the therapy works best alongside changes in eating habits and ongoing support.
Thank you for tuning in to Ozempic Weightloss Unlocked. If you found today’s update helpful, be sure to subscribe for more news and expert insights on this quickly evolving topic. This has been a quiet please production, for more check out quiet please dot ai.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
Welcome to Ozepic Weight Loss Unlocked, the podcast where the
science and the stories around ozempic are put into focus
for anyone curious about medical breakthroughs, health and real world results.
Today we dive into the latest findings shaking up the
world of weight management with ozempic, a brand aim for semaglutide.
New research published mid September in the Lancet Diabetes and
(00:23):
Endochronology shows that a triple sized weekly dose of ozepic
specifically seven point two milligrams, helped people with obesity lose
even more weight in the currently approved lower dose. Adults
who took this higher dose lost on average newly nineteen
per cent of their body weight. Nearly half of participants
on this regimen lost at least twenty percent, and a
(00:46):
third lost a quarter or more. Similar benefits were seen
for those with type two diabetes, the higher dose, leading
to a thirteen percent weight loss compared to ten percent
for the lower dose. But there is more than just
(01:08):
the numbers on the scale. Participants on the higher dose
saw improvements in waste circumference, blood pressure, blood sugar and
cholesterol numbers. Importantly, the higher dose was found to be
both safe and generally well tolerated. The most frequent issues
were digestive like nausea and diarrhea, but these tended to
(01:30):
resolve over time, with no increased risk of severe low
blood sugar or other serious events. Researches from the Wharton
Medical Clinic in Canada concluded that even greater health improvements
could be reached in the future that they called for
more research into the long term effects and safety as
use expands. Adding to the buzz, a recent study out
(01:53):
of Denmark raises important questions about how long people actually
stick with their zepic for weight management. According to research
presented at the annual meeting of the European Association for
the Study of Diabetes, more than half of adults who
began using the drug for weight loss ended up quitting
within one year. Factors behind this drop off included cost,
(02:13):
side effects and potential health complications. When treatment is stopped,
most people regain weight, highlighting that ozempic is not a
short term fix and needs to be taken long term
for sustainable results. The findings raise red flags since discontinuing
the medication can undermine hard won health improvements, and the
high price also risks making access unequal. Ozepic is not
(02:35):
just for the scale, it has heart protective effects too.
Novo Nordisk, the pharmaceutical company behind the drug, released results
from the REACH trial showing that once weekly ozepic reduced
the risk of heart attack, stroke, or hospitalization for heart
failure by a significant twenty five percent compared to an
older medication called doula glutide. That is a substantial bonus,
(02:58):
especially for those with both obesity and cardiovascular risk Collectors.
Researchers are also learning that how you eat can affect
how well ozepic works. A team from Kyoto University found
that people who eat in response to sites and smells
of food are more likely to see weight loss benefits
from ozepic compared to those who eat mainly for emotional reasons.
(03:18):
Those with emotional eating patterns might require additional behavioral or
psychological support for the medication to be most effective. The
science is clear, GOLP one receptor agonists like ozeenpic can
be life changing, delivering substantial and safe weight loss along
with significant improvements for blood sugar, heart health, and metabolic
(03:39):
risk factors. But to sustain progress, long term commitment is key,
and the therapy works best alongside changes and eating habits
and ongoing support. Thank you for tuning in to Ozepic
Weight Loss Unlocked. If you found today's update helpful, be
sure to subscribe for more news and expert insights on
(03:59):
this quick evolving topic. This has been a quiet please production.
For more check out quiet please dot ai
Welcome to Ozepic Weight Loss Unlocked, the podcast where the
science and the stories around ozempic are put into focus
for anyone curious about medical breakthroughs, health and real world results.
Today we dive into the latest findings shaking up the
world of weight management with ozempic, a brand aim for semaglutide.
New research published mid September in the Lancet Diabetes and
(00:23):
Endochronology shows that a triple sized weekly dose of ozepic
specifically seven point two milligrams, helped people with obesity lose
even more weight in the currently approved lower dose. Adults
who took this higher dose lost on average newly nineteen
per cent of their body weight. Nearly half of participants
on this regimen lost at least twenty percent, and a
(00:46):
third lost a quarter or more. Similar benefits were seen
for those with type two diabetes, the higher dose, leading
to a thirteen percent weight loss compared to ten percent
for the lower dose. But there is more than just
(01:08):
the numbers on the scale. Participants on the higher dose
saw improvements in waste circumference, blood pressure, blood sugar and
cholesterol numbers. Importantly, the higher dose was found to be
both safe and generally well tolerated. The most frequent issues
were digestive like nausea and diarrhea, but these tended to
(01:30):
resolve over time, with no increased risk of severe low
blood sugar or other serious events. Researches from the Wharton
Medical Clinic in Canada concluded that even greater health improvements
could be reached in the future that they called for
more research into the long term effects and safety as
use expands. Adding to the buzz, a recent study out
(01:53):
of Denmark raises important questions about how long people actually
stick with their zepic for weight management. According to research
presented at the annual meeting of the European Association for
the Study of Diabetes, more than half of adults who
began using the drug for weight loss ended up quitting
within one year. Factors behind this drop off included cost,
(02:13):
side effects and potential health complications. When treatment is stopped,
most people regain weight, highlighting that ozempic is not a
short term fix and needs to be taken long term
for sustainable results. The findings raise red flags since discontinuing
the medication can undermine hard won health improvements, and the
high price also risks making access unequal. Ozepic is not
(02:35):
just for the scale, it has heart protective effects too.
Novo Nordisk, the pharmaceutical company behind the drug, released results
from the REACH trial showing that once weekly ozepic reduced
the risk of heart attack, stroke, or hospitalization for heart
failure by a significant twenty five percent compared to an
older medication called doula glutide. That is a substantial bonus,
(02:58):
especially for those with both obesity and cardiovascular risk Collectors.
Researchers are also learning that how you eat can affect
how well ozepic works. A team from Kyoto University found
that people who eat in response to sites and smells
of food are more likely to see weight loss benefits
from ozepic compared to those who eat mainly for emotional reasons.
(03:18):
Those with emotional eating patterns might require additional behavioral or
psychological support for the medication to be most effective. The
science is clear, GOLP one receptor agonists like ozeenpic can
be life changing, delivering substantial and safe weight loss along
with significant improvements for blood sugar, heart health, and metabolic
(03:39):
risk factors. But to sustain progress, long term commitment is key,
and the therapy works best alongside changes and eating habits
and ongoing support. Thank you for tuning in to Ozepic
Weight Loss Unlocked. If you found today's update helpful, be
sure to subscribe for more news and expert insights on
(03:59):
this quick evolving topic. This has been a quiet please production.
For more check out quiet please dot ai
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Cardiac Cowboys
The heart was always off-limits to surgeons. Cutting into it spelled instant death for the patient. That is, until a ragtag group of doctors scattered across the Midwest and Texas decided to throw out the rule book. Working in makeshift laboratories and home garages, using medical devices made from scavenged machine parts and beer tubes, these men and women invented the field of open heart surgery. Odds are, someone you know is alive because of them. So why has history left them behind? Presented by Chris Pine, CARDIAC COWBOYS tells the gripping true story behind the birth of heart surgery, and the young, Greatest Generation doctors who made it happen. For years, they competed and feuded, racing to be the first, the best, and the most prolific. Some appeared on the cover of Time Magazine, operated on kings and advised presidents. Others ended up disgraced, penniless, and convicted of felonies. Together, they ignited a revolution in medicine, and changed the world.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.